Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

HIV-1 Env antibodies: are we in a bind or going blind?

Nature Medicine volume 18, pages 346–347 (2012)Cite this article

Subjects

To the Editor:

In his Nature Medicine 'Bedside to Bench' paper, Tom Hope makes interesting points about the possible roles of neutralizing and non-neutralizing antibodies (NAbs and non-NAbs, respectively) in protection against HIV-1 infection in the RV144 vaccine trial1. The efficacy in that trial ranged from a significant 31.2% to a non-significant 26.2%, depending on the statistical method used; when volunteers who became infected with HIV-1 before receiving the full vaccine regimen were excluded, the vaccine had no significant efficacy2,3. Opinions, therefore, vary on how much this trial should influence the future direction of vaccine research.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hope, T.J. Nat. Med. 17, 1195–1197 (2011).

    Article  CAS  Google Scholar 

  2. Rerks-Ngarm, S. et al. N. Engl. J. Med. 361, 2209–2220 (2009).

    Article  CAS  Google Scholar 

  3. Gilbert, P.B. et al. J. Infect. Dis. 203, 969–975 (2011).

    Article  Google Scholar 

  4. Gilbert, P.B. et al. J. Infect. Dis. 191, 666–677 (2005).

    Article  CAS  Google Scholar 

  5. Chohan, B.H. et al. Curr. HIV Res. 8, 596–601 (2010).

    Article  CAS  Google Scholar 

  6. Haynes, B. AIDS Vaccine 2011 Conference, Bangkok, Thailand (2011).

  7. Follmann, D. Biometrics 62, 1161–1169 (2006).

    Article  Google Scholar 

  8. Moore, J.P. et al. Science 320, 753–755 (2008).

    Article  CAS  Google Scholar 

  9. Shibata, R. et al. Nat. Med. 5, 204–210 (1999).

    Article  CAS  Google Scholar 

  10. Mascola, J.R. et al. Nat. Med. 6, 207–210 (2000).

    Article  CAS  Google Scholar 

  11. Parren, P.W. et al. J. Virol. 75, 8340–8347 (2001).

    Article  CAS  Google Scholar 

  12. Burton, D.R. et al. Proc. Natl. Acad. Sci. USA 108, 11181–11186 (2011).

    Article  CAS  Google Scholar 

  13. Onyango-Mukumbi, C. et al. J. Acq. Immun. Def. Synd. 58, 399–407 (2011).

    Article  Google Scholar 

  14. Mascola, J.R. et al. J. Virol. 73, 4009–4018 (1999).

    CAS  PubMed Central  Google Scholar 

  15. Shibata, R. et al. Nat. Med. 5, 204–210 (1999).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Weill Cornell Medical College, New York, New York, USA

    John P Moore

Authors
  1. John P Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John P Moore.

Ethics declarations

Competing interests

J.P.M. is listed on a patent application for the use of HIV-1 Env trimers to induce virus-binding and non-neutralizing antibodies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moore, J. HIV-1 Env antibodies: are we in a bind or going blind?. Nat Med 18, 346–347 (2012). https://doi.org/10.1038/nm.2689

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2689

This article is cited by

Search

Advanced search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology